TickerFacts.

NewAmsterdam Pharma Co N.V. (NAMS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$683.43M
As of 2025-12-31
$631.42M
As of 2026-06-30
+16.7%
3-year compound annual growth
$757.50M2021-12-31: -$113.82M2022-12-31: $430.07M2023-12-31: $288.39M2024-12-31: $757.50M2025-12-31: $683.43M$683.43M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$683.43M-9.8%2026-02-18, Balance as of period end
2024-12-31$757.50M+162.7%2026-02-18, Balance as of period end
2023-12-31$288.39M-32.9%2026-02-18, Balance as of period end
2022-12-31$430.07Mn/m2025-02-26, Balance as of period end
2021-12-31-$113.82Mn/a2024-02-28, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$683.43M-9.8%
Alumis Inc. (ALMS)2025-12-31$301.30M+15.8%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$37.28Mn/m
Scynexis Inc (SCYX)2025-12-31$49.38M-10.4%
Evofem Biosciences, Inc. (EVFM)2025-12-31-$74.34Mn/m
Entrada Therapeutics, Inc. (TRDA)2025-12-31$306.13M-28.6%
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$22.81M-20.9%
Celularity Inc (CELU)2025-12-31-$38.06Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31$26.43M+51.0%

Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗